New combo tackles rare, aggressive lymphoma

NCT ID NCT04139304

Recruiting now Disease control Sponsor: AIDS Malignancy Consortium Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests adding daratumumab, an antibody that targets a protein on cancer cells, to standard chemotherapy for people with newly diagnosed plasmablastic lymphoma, a rare and fast-growing cancer. The trial includes up to 15 participants, with or without HIV. The main goal is to see if the combination is feasible and safe, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab (a targeted antibody) plus a combination of chemotherapy drugs (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)
What this could lead to: If successful, this could point toward a more effective first treatment for plasmablastic lymphoma, a rare and aggressive cancer.
What could go wrong: This is a very early, small feasibility study with only 15 participants. It is not designed to prove the treatment works, only that it can be given. Side effects from the added drug and chemo are expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE I DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma plasmablastic lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANN ARBOR STAGE I DIFFUSE LARGE B-CELL LYMPHOMA ANN ARBOR STAGE II DIFFUSE LARGE B-CELL LYMPHOMA ANN ARBOR STAGE III DIFFUSE LARGE B-CELL LYMPHOMA ANN ARBOR STAGE IV DIFFUSE LARGE B-CELL LYMPHOMA PLASMABLASTIC LYMPHOMA

Contacts and locations

Locations

Johns Hopkins University/Sidney Kimmel Cancer Center
RECRUITING

Baltimore, Maryland, 21231, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
The Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Illinois at Chicago
RECRUITING

Chicago, Illinois, 60612, United States
University of Miami Miller School of Medicine
RECRUITING

Miami, Florida, 33136, United States
University of North Carolina - Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27514, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.